NasdaqGS:RXRXBiotechs
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks
Recursion Pharmaceuticals recently reported first-quarter 2026 results showing revenue of US$6.47 million and a net loss of US$117.5 million, while founder Chris Gibson decided not to seek re-election to the board after June 2026 but will continue as an advisor.
At the same time, investors are closely watching the company’s advancing AI-enabled pipeline, including REC-4881 and REC-1245, amid ongoing FDA engagement on potential registrational pathways.
We’ll now examine how Recursion’s FDA...